Background: Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths globally, with a dismal prognosis for advanced patients. Lenvatinib, a first-line anti-angiogenic agent, has improved clinical outcome... ...

请注册登录后继续浏览